A drug named Orfadin® (nitisinone) an oral suspension formulation for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) has been granted a patent by the EPO. Hereditary Tyrosinaemia type-1 (HT-1) is a rare genetic disease affecting children. [More]
top of page
Search
Recent Posts
See AllGeneral Motors has secured an Indian patent on a hybrid powertrain control system for vehicles. The patent rights are currently assigned...
Taking into consideration the Delhi High court’s order staying the abandonment orders passed by the Trademarks Office, the Registrar of...
The order of the Delhi High Court allows the Competition Commission of India (CCI) to attend to complaints on abuse of dominance of...
bottom of page
Comments